ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

被引：38

作者：

Gregorj, Chiara

Ricciardi, Maria R.

Petrucci, Maria T.

Scerpa, Maria C.

De Cave, Fabiana

Fazi, Paola

Vignetti, Marco

Vitale, Antonella

Mancini, Marco

Cimino, Giuseppe

Palmieri, Salvatore

Di Raimondo, Francesco

Specchia, Giorgina

Fabbiano, Francesco

Cantore, Nicola

Mosna, Federico

Camera, Andrea

Luppi, Mario

Annino, Luciana

Miraglia, Eustachio

Fioritoni, Giuseppe

Ronco, Francesca

Meloni, Giovanna

Mandelli, Franco

Andreeff, Michael

Milella, Michele

Foa, Robin

Tafuri, Agostino ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy

[2] Ctr Data, Gruppo Italiano MEA GIMEMA Fdn, Rome, Italy

[3] Azienda Osped Rilievo Nazl A Cardarelli, Div Ematol, Naples, Italy

[4] Univ Studi Catania, Osped Ferrarotto, Cattedra Ematol, Catania, Italy

[5] Univ Studi Bari, Unit Operativa Ematol 1, Bari, Italy

[6] Azienda Osped V Cervello, Div Ematol, Palermo, Italy

[7] Azienda Osped SG Moscati, Avellino, Italy

[8] Univ Studi Verona, Div Ematol, Policlin GB Rossi, Verona, Italy

[9] Univ Naples Federico II, Naples, Italy

[10] Complesso Osped S Giovanni Addolorata, Unit Operativa Ematol, Rome, Italy

[11] ASL Napoli 1 Osped San Giovanni Bosco, Div Ematol, Naples, Italy

[12] Azienda USL, Unit Operativa Ematol Clin, Pescara, Italy

[13] Azienda Osped Bianchi Melacrino Morelli Reggio, Dipartimento Ematol Oncol, Calabria, Italy

[14] Univ Texas, MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Houston, TX 77030 USA

[15] Regina Elena Inst Canc Res, Div Med Oncol, Rome, Italy

来源：

BLOOD | 2007年 / 109卷 / 12期

关键词：

D O I：

10.1182/blood-2006-05-021071

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Extracellular signal-regulated kinase1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukernogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattle Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P =.013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P =.027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.

引用

页码：5473 / 5476

页数：4

共 21 条

[1] Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study [J].

Annino, L ;

Vegna, ML ;

Camera, A ;

Specchia, G ;

Visani, G ;

Fioritoni, G ;

Ferrara, F ;

Peta, A ;

Ciolli, S ;

Deplano, W ;

Fabbiano, F ;

Sica, S ;

Di Raimondo, F ;

Cascavilla, N ;

Tabilio, A ;

Leoni, P ;

Invernizzi, R ;

Baccarani, M ;

Rotoli, B ;

Amadori, S ;

Mandelli, F .

BLOOD, 2002, 99 (03) :863-871

[2] Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells [J].

Barata, JT ;

Silva, A ;

Brandao, JG ;

Nadler, LM ;

Cardoso, AA ;

Boussiotis, VA .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (05) :659-669

[3] Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors [J].

Chow, S ;

Patel, H ;

Hedley, DW .

CYTOMETRY, 2001, 46 (02) :72-78

[4] Pharmacological inhibitors of MAPK pathways [J].

English, JM ;

Cobb, MH .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (01) :40-45

[5] PROGNOSTIC FACTORS IN A MULTICENTER STUDY FOR TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA IN ADULTS [J].

HOELZER, D ;

THIEL, E ;

LOFFLER, H ;

BUCHNER, T ;

GANSER, A ;

HEIL, G ;

KOCH, P ;

FREUND, M ;

DIEDRICH, H ;

RUHL, H ;

MASCHMEYER, G ;

LIPP, T ;

NOWROUSIAN, MR ;

BURKERT, M ;

GERECKE, D ;

PRALLE, H ;

MULLER, U ;

LUNSCKEN, C ;

FULLE, H ;

HO, AD ;

KUCHLER, R ;

BUSCH, FW ;

SCHNEIDER, W ;

GORG, C ;

EMMERICH, B ;

BRAUMANN, D ;

VAUPEL, HA ;

VONPALESKE, A ;

BARTELS, H ;

NEISS, A ;

MESSERER, D .

BLOOD, 1988, 71 (01) :123-131

[6] ABL oncogenes and phosphoinositide 3-kinase:: Mechanism of activation and downstream effectors [J].

Kharas, NG ;

Fruman, DA .

CANCER RESEARCH, 2005, 65 (06) :2047-2053

[7]

KOMBLAU MM, 2001, BLOOD, V98, pA716

[8] The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia [J].

Lee, JT ;

McCubrey, JA .

LEUKEMIA, 2002, 16 (04) :486-507

[9]

LEWAS TS, 1998, ADV CANCER RES, V74, P149

[10] Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro [J].

Meng, XW ;

Chandra, J ;

Loegering, D ;

Van Becelaere, K ;

Kottke, TJ ;

Gore, SD ;

Karp, JE ;

Sebolt-Leopold, J ;

Kaufmann, SH .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (47) :47326-47339

← 1 2 3 →